LTRN Lantern Pharma Inc. Stock Quote

LTRN [NASD]

Index	-	P/E	-	EPS (ttm)	-1.12	Insider Own	36.82%	Shs Outstand	10.07M	Perf Week	-5.57%
Market Cap	154.52M	Forward P/E	-	EPS next Y	-1.43	Insider Trans	0.00%	Shs Float	6.37M	Perf Month	-11.81%
Income	-7.90M	PEG	-	EPS next Q	-0.26	Inst Own	27.20%	Short Float	3.63%	Perf Quarter	-15.70%
Sales	-	P/S	-	EPS this Y	-135.90%	Inst Trans	73.40%	Short Ratio	1.67	Perf Half Y	-10.66%
Book/sh	8.11	P/B	1.86	EPS next Y	-32.40%	ROA	-20.90%	Target Price	-	Perf Year	-
Cash/sh	7.95	P/C	1.90	EPS next 5Y	-	ROE	-21.60%	52W Range	10.40 - 24.84	Perf YTD	-21.61%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-39.25%	Beta	-
Dividend %	-	Quick Ratio	124.10	Sales past 5Y	-	Gross Margin	-	52W Low	45.10%	ATR	1.26
Employees	11	Current Ratio	124.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	43.33	Volatility	8.70% 7.65%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-207.60%	Profit Margin	-	Rel Volume	0.31	Prev Close	15.62
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 03 AMC	Payout	-	Avg Volume	138.37K	Price	15.09
Recom	1.50	SMA20	-3.68%	SMA50	-12.85%	SMA200	-9.43%	Volume	43,485	Change	-3.39%

May-10-21 06:35AM	Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth Simply Wall St.
May-03-21 04:32PM	Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights PR Newswire +6.46%
02:45PM	Lantern Pharma Inc to Host Earnings Call ACCESSWIRE
07:00AM	Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform PR Newswire
Apr-29-21 07:00AM	Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company's Progress in the Development of Biopharma Collaborations and Partnerships and Advancing the Company's Strategy to Develop the World's Largest A.I. Platform for Oncology-Focused Drug Development & Rescue PR Newswire
Apr-26-21 04:30PM	Lantern Pharma to Host First Quarter 2021 Operating and Financial Results Conference Call on May 3, 2021 at 4:30 p.m. ET PR Newswire
07:45AM	Lantern Pharma Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget PR Newswire
Apr-06-21 07:45AM	Lantern Pharma to Participate in the Virtual 20th Annual Needham Healthcare Conference PR Newswire
Apr-01-21 07:59AM	Lantern Pharma Expands Portfolio of Cancer Opportunities for LP-184 with ATRT Pediatric Brain Tumor Collaboration with Johns Hopkins PR Newswire +9.65%
Mar-25-21 02:45PM	Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference Benzinga
Mar-23-21 07:48AM	Lantern Pharma to Present New Data Supporting the Advancement of LP-184 at the AACR Virtual Annual Meeting 2021 PR Newswire -5.03%
Mar-22-21 09:10AM	LTRN: New Programs, Pipeline Progress, Raise, and RADR Zacks Small Cap Research
Mar-17-21 07:00AM	Lantern Pharma Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties PR Newswire
Mar-12-21 09:00AM	Lantern Pharma Interview to Air on Bloomberg TV in the US on the RedChip Money Report® PR Newswire
Mar-11-21 03:21AM	How Much Are Lantern Pharma Inc. (NASDAQ:LTRN) Insiders Spending On Buying Shares? Simply Wall St. +9.85%
Mar-10-21 04:00PM	Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights PR Newswire
12:45PM	Lantern Pharma Inc to Host Earnings Call ACCESSWIRE
Mar-03-21 07:00AM	Lantern Pharma to Host Fourth Quarter and Fiscal Year End 2020 Operating and Financial Results Conference Call on March 10, 2021 at 4:00 p.m. ET PR Newswire
Feb-22-21 08:52AM	Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer Treatment Benzinga
Feb-16-21 06:35AM	LTRN: $69 Million Raise & New Programs Spark Price Target Increase Zacks Small Cap Research
Jan-20-21 04:00PM	Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full Exercise of Underwriter's Over-Allotment Option PR Newswire
Jan-14-21 09:30PM	Lantern Pharma Announces Pricing of $60 Million Public Offering PR Newswire -6.69%
Jan-06-21 04:20AM	LTRN: Lantern Calls On Califia for Antibody Drug Conjugates Zacks Small Cap Research
Jan-04-21 07:00AM	Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma PR Newswire
Dec-17-20 07:00AM	Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma PR Newswire +8.49%
Dec-15-20 07:00AM	Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers PR Newswire
Dec-11-20 02:32AM	What Kind Of Investors Own Most Of Lantern Pharma Inc. (NASDAQ:LTRN)? Simply Wall St.
Dec-08-20 08:32AM	Lantern Pharma's A.I. Platform Is Helping To Transform The Probability Of Success In Oncology Drug Development & Clinical Trials Benzinga
Nov-24-20 09:30AM	Diamond Equity Research 2020 Virtual Emerging Growth Invitational ACCESSWIRE
07:30AM	Lantern Pharma Announces Upcoming Conference Presentations PR Newswire
Nov-10-20 04:53AM	LTRN: 3Q:20 Update Zacks Small Cap Research
Oct-29-20 03:59PM	Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress PR Newswire
02:00PM	Lantern Pharma Incto Host Earnings Call ACCESSWIRE
Oct-22-20 07:00AM	Lantern Pharma to Host Third Quarter 2020 Operating and Financial Results Conference Call on October 29, 2020 at 4:00 p.m. ET PR Newswire +6.30%
Oct-19-20 11:35AM	LTRN: Reviving Failed Oncology Drugs with AI Zacks Small Cap Research -11.07%
Oct-05-20 07:46AM	Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent PR Newswire
Sep-22-20 07:55AM	Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer PR Newswire
Sep-11-20 11:46AM	Lantern Pharma Inc. (NASDAQ:LTRN) Insiders Increased Their Holdings Simply Wall St. +25.18%
Sep-04-20 06:01PM	LD Micro 360 Companies: --Set to Present this Week. ACCESSWIRE
Aug-27-20 07:55AM	Lantern Pharma Announces Upcoming Conference Presentations PR Newswire
Aug-18-20 01:29PM	AI Is Booming: Here Are 3 Stocks Analysts Are Betting On TipRanks +7.77%
Aug-14-20 02:25PM	Lantern Pharma Interview to Air on Bloomberg International on the RedChip Money Report PR Newswire
Aug-05-20 09:00AM	LD Micro - Announces Preliminary List of Presenters for the LD 500 ACCESSWIRE
Jul-30-20 06:57AM	Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress PR Newswire
Jul-24-20 07:56AM	Lantern Pharma to Host Second Quarter 2020 Operating and Financial Results Conference Call on July 30, 2020 PR Newswire
Jul-20-20 07:55AM	Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Glioblastoma PR Newswire -6.10%
Jul-16-20 11:00AM	'Zooming with LD' to Feature 10 Distinct Companies July 20th-31st ACCESSWIRE
Jun-29-20 08:45AM	Lantern Pharmas Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Companys Path to 1 Billion Data Points Curated Specifically for Oncology Drug Development and Drug Response Prediction GlobeNewswire +5.13%
Jun-17-20 09:23AM	Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting GlobeNewswire -9.78%
Jun-15-20 03:53PM	Lantern Pharma Announces Closing of Initial Public Offering GlobeNewswire
Jun-11-20 08:12AM	The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO Benzinga

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience